Dermatology

Explore innovative isotretinoin strategies for acne vulgaris, balancing efficacy and tolerability to enhance patient outcomes and long-term remission.

The expanded indications now include adolescents with hidradenitis suppurativa aged 12 and older and pediatrics with uveitis aged 2 and older.

Cemiplimab's approval is supported by findings from the C-POST clinical trial.

Johnson & Johnson presented new long-term data of icotrokinra from ICONIC-LEAD, along with data from ICONIC-ADVANCE indicating head-to-head superiority with standard-of-care deucravacitinib.

The approval is supported by findings from the INTEGUMENT-PED trial and the INTEGUMENT-OLE long-term extension study.

A phase 3 study shows SYSA1902, a biosimilar to Stelara, is clinically equivalent for treating moderate to severe plaque psoriasis.

Remibrutinib gains FDA approval as the first oral treatment for chronic hives, offering hope for patients unresponsive to standard therapies.

The FDA approves guselkumab, the first IL-23 inhibitor for pediatric psoriasis and psoriatic arthritis, enhancing treatment options for children.

With this approval, an effective, nonsteroidal treatment option is available for young patients.

Investigators from the phase 3 COAST 1 trial demonstrated the efficacy and safety of amlitelimab in patients with moderate-to-severe atopic dermatitis.

Biosimilars can be a more affordable and accessible treatment option for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Prompt identification and appropriate clinical intervention are critical.

Tildrakizumab 100 mg shows significant efficacy in treating psoriatic arthritis, achieving key clinical trial end points and offering hope for patients.

The approval represents a major advancement for patients with moderate-to-severe chronic hand eczema, as delgocitinib becomes the first treatment available for this population in the US.

The complete response letter (CRL) did not raise safety concerns, but stated the IGNYTE trial was inadequate and did not provide substantial evidence of effectiveness.

Vitamin C enhances skin health by promoting epidermal cell growth and regeneration, offering a potential solution for aging and thinning skin.

Hulio shows comparable efficacy and safety to Humira in treating chronic plaque psoriasis, supporting its FDA interchangeability status.

The FDA approves dupilumab as the first targeted treatment for bullous pemphigoid, offering hope for patients with this debilitating skin condition.

Discover essential tips for sunburn prevention and treatment, insect bite protection, and effective remedies for outdoor fun with family.

Nemolizumab shows promising long-term efficacy in reducing itch and skin lesions for atopic dermatitis, enhancing quality of life for patients.

The subcutaneous infusion is indicated for pediatric patients aged 6 to 17 years who weigh less than 60 kg.

Enhanced dermatologic management reduces skin rash and improves quality of life for patients with EGFR-mutant non-small cell lung cancer.

Embedding a pharmacist in the dermatology clinic improved clinical and financial outcomes.

This indication is for adult and pediatric patients aged 12 and older with plaque psoriasis of the scalp and body.

Patients should understand that routine skin care is an important facet in the overall management of diabetes.